LOGIN  |  REGISTER
Amneal Pharmaceuticals

Novo Integrated Sciences (NASDAQ: NVOS) Stock Quote

Last Trade: US$0.50 0.05 10.10
Volume: 616,047
5-Day Change: 0.72%
YTD Change: -38.79%
Market Cap: US$9.570M

Latest News From Novo Integrated Sciences

BELLEVUE, Wash. / Apr 15, 2024 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the second fiscal quarter ended February 29, 2024. Robert... Read More
Both the Mast Hill $3,500,000 Note and the FirstFire $277,777 Note were Paid in Full with Cash Proceeds from the Streeterville Note BELLEVUE, Wash. / Apr 11, 2024 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today the Company has entered into a securities purchase agreement, dated April 5, 2024, with Streeterville Capital, LLC (“Streeterville”) pursuant to which the... Read More
BELLEVUE, Wash. / Mar 26, 2024 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: Purchase and Sale Agreement – Ophir Collection: As previously disclosed, on November 21, 2023 Novo entered into a Purchase and Sale Agreement (“Ophir Agreement”) between the Company and Blake Alsbrook, solely in his capacity... Read More
BELLEVUE, Wash. / Feb 21, 2024 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International, LLC (“CCI”), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Services Agreement (the “Agreement”), with Futura Surgicare Pvt Ltd (“Futura”), an India-based leading manufacturer of wound closure and surgical products that are marketed and... Read More
BELLEVUE, Wash. / Feb 16, 2024 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announces today Mr. Robert Oliva has been appointed as the Company’s new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company’s Chief Operating Officer and as a member of the Company’s Board of Directors. Mr. Oliva has over 35 years of ownership and proven business development... Read More
BELLEVUE, Wash. / Jan 22, 2024 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the first fiscal quarter ended November 30, 2023. Robert... Read More
BELLEVUE, Wash. / Dec 19, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announces today Blacksheep Trust (“Blacksheep”), a New York-based private express trust settled for the purposes of Benevolent Services with (i) a 33% allocation to charitable services, and (ii) 67% allocation to social economic development, has filed a UCC-3 Financing Statement Amendment with the State of... Read More
BELLEVUE, Wash. / Dec 14, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2023. Robert Mattacchione,... Read More
BELLEVUE, Wash. / Dec 05, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) proudly announces the signing of a Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India (“PCHPL”). This partnership initiates a strategic initiative to introduce new products and state-of-the-art healthcare technologies to the Indian market, with plans to extend healthcare related products... Read More
BELLEVUE, Wash. / Dec 04, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the United States District Court for the Central District of California has approved the Purchase and Sale Agreement (“PSA”) which provides for the Company to acquire a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute of America, known as the “Ophir... Read More
BELLEVUE, Wash. / Nov 24, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the Company has received notice from The Nasdaq Capital Market, LLC (“Nasdaq”), dated November 22, 2023, informing Novo that it has regained compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing on Nasdaq. As previously... Read More
BELLEVUE, Wash. / Nov 06, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that the Company will undertake a reverse stock split of its common stock at a ratio of 1-for-10 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective immediately after the close of trading on the Nasdaq Capital Market ("Nasdaq") on November 6, 2023 (the... Read More
BELLEVUE, Wash. / Nov 06, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced that RC Consulting Group LLC (“RC”) has advised that the final phase for the withdrawal/payment to Novo of the unsecured 15-year $70,000,000 promissory note with RC in favor of SCP Tourbillion Monaco for a lump sum debt funding of $57,000,000, less fees and expenses, has been initiated and... Read More
BELLEVUE, Wash. / Nov 03, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the issuance of the underlying One Billion Dollar gold backed bond (the “Bond”) specific to the previously disclosed Master Collateral Transfer Agreement. The issuance of the Bond is the initial step in the establishment of the instrument to commence the legal transfer of the collateral for... Read More
BELLEVUE, Wash. / Oct 24, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company’s Board of Directors has approved the repurchase of up to $5 million of the Company's outstanding common stock ("shares") from time to time in the open market at prevailing market prices or in privately negotiated transactions. Pending receipt of funds from the unsecured... Read More
BELLEVUE, Wash. / Oct 06, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today provides an update with respect to the following previously disclosed pending transactions: (i) the Blacksheep Trust One Billion Dollar Master Collateral Transfer Agreement (the “Collateral Transfer Facility”), (ii) the Letter of Funding Commitment for a direct investment in the Company of... Read More
One Billion Dollar Collateral Transfer through Blacksheep Trust BELLEVUE, Wash. / Sep 28, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced Novo and Blacksheep Trust have signed a One Billion Dollar Master Collateral Transfer Agreement (the “Master Agreement”) for the purpose and general use of monetization by Novo for a period of up to 15 years. The One Billion... Read More
September 29, 2023 Shareholder Meeting Voting Update BELLEVUE, Wash. / Sep 21, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: Annual Meeting Shareholder Voting . For shareholders that have not voted in connection with the upcoming September 29, 2023 annual shareholder meeting, please vote as soon... Read More
Partners with NOYEM Global Foreign Trade and Consultancy Inc. for Distribution in Turkey BELLEVUE, Wash. / Sep 13, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that its IoNovo for Kids pure iodine oral spray has been granted a registration number and received regulatory approval by Turkey’s Ministry of Health as a dietary supplement determined to be safe,... Read More
BELLEVUE, Wash. / Sep 08, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to the Company’s Board of Directors (the “Board”) conducting a strategic review of the Company to include implementing a future share repurchase program. The Board is considering and evaluating a share buyback of up to $5,000,000 upon closing and full funding of... Read More
Compliance Review Affirmed for Completion of Debt Funding Transaction BELLEVUE, Wash. / Aug 31, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company received an Underwriting Clearance Notice from RC Consulting Group LLC informing Novo that the underwriting analysis process and compliance review for the transaction between Novo and RC Consulting LLC in... Read More
Team Canada Delegation to be led by Honorable Mary Ng, Canada’s Minister of International Trade, Export Promotion, Small Business and Economic Development BELLEVUE, Wash. / Aug 24, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that Acenzia, a nutraceutical manufacturer and a Canadian subsidiary of Novo, has been invited to join the Team Canada Trade Mission to... Read More
BELLEVUE, Wash. / Aug 22, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that its IoNovo Iodine product has been granted a registration number and received regulatory approval by Turkey’s Ministry of Health as a dietary supplement determined to be safe, effective, of high quality, and eligible for sale in Turkey. For decades, the global medical community has... Read More
BELLEVUE, Wash. / Aug 15, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: Parties continue to work toward closing SWAG Agreement: As previously disclosed, Novo entered into a share purchase agreement (the “SWAG Agreement”) with SwagCheck Inc. (“SWAG”) and the shareholders of SWAG, pursuant to which... Read More
Food-based commodity farming on up to 9 million hectares in Kenya BELLEVUE, Wash. / Aug 15, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the Company and Farm 7 Group Inc., a Canada corporation (“F7”), have entered into a joint venture agreement (the “JV Agreement”) relating to the development, administration and arrangement of structured financing for the... Read More
BELLEVUE, Wash. / Jul 17, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2023. Robert Mattacchione,... Read More
Joint Venture Collaboration with Sheikh Khaled bin Mohammad bin Fahad Al Thanayan and his Global Healthcare Organization BELLEVUE, Wash. / Jun 06, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the Company has received a Letter of Funding Commitment for a direct investment in the Company of USD $40,000,000 from Sheikh Khaled bin Mohammad bin Fahad Al Thanayan... Read More
BELLEVUE, Wash. / May 26, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended February 28, 2023. Robert Mattacchione,... Read More
BELLEVUE, Wash. / May 24, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended November 30, 2022. Robert Mattacchione,... Read More
The Company to Receive a Lump Sum of $57,000,000 Note has a non-compounding yield of 1.52% (zero coupon) per annum BELLEVUE, Wash. / Apr 27, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the issuance of an unsecured 15-year $70,000,000 promissory note with RC Consulting LLC in favor of SCP Tourbillion Monaco (the “Buyer”), for a lump sum debt funding of... Read More
BELLEVUE, Wash. / Apr 03, 2023 / Business Wire / Novo Integrated Sciences, Inc. ( NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2022. Robert Mattacchione,... Read More
BELLEVUE, Wash. / Mar 24, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: As previously reported, on December 23, 2022, Novo entered into a Share Purchase Agreement (the “SWAG Agreement”) with SwagCheck Inc. (“SWAG”) and the shareholders of SWAG, pursuant to which Novo agreed to purchase 100% of... Read More
BELLEVUE, Wash. / Jan 30, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today reported that it received a notice on January 25, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) as a result of its failure... Read More
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: As previously reported, on December 23, 2022, Novo entered into a Share Purchase Agreement (the “SWAG Agreement”) with SwagCheck Inc. (“SWAG”) and the shareholders of SWAG, pursuant to which Novo agreed to purchase 100% of SWAG’s outstanding shares. SWAG holds a specific... Read More
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today reported that it received a notice (the “Notice) on December 15, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to timely file its... Read More
Astria Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB